Alzheimer's Disease Shows Promise for Treatment with Two Approved Cancer Medications, According to Recent Studies
Two FDA-approved drugs, Letrozole and Irinotecan, originally used for treating cancer, have shown promising results in the fight against Alzheimer's disease. These drugs have been found to reduce tau protein clumps in the brain and improve cognitive functions like memory and learning in mouse models.
Before these drugs can be used to treat Alzheimer's, researchers must evaluate their potential side effects in this new context. As of now, Alzheimer's disease affects over 55 million people worldwide, a number expected to rise as the global population ages. The quicker pathway to clinical trials for these drugs compared to entirely new medications is due to their FDA approval.
Researchers at the University of California, San Francisco (UCSF) and the Gladstone Institutes have discovered a potential new approach for treating Alzheimer's disease using these two drugs. Letrozole seems to help neurons, the cells responsible for transmitting information, while Irinotecan works on glial cells, which support neurons.
The combination of Letrozole and Irinotecan reduces tau protein clumps in the brain of mouse models, a key feature of Alzheimer's. Mice treated with the drugs demonstrated improvements in learning and memory tasks, which are often severely impaired in Alzheimer's patients.
Letrozole works through aromatase inhibition linked to estrogen signaling and synaptic plasticity in neurons, while Irinotecan acts through anti-inflammatory effects in glial cells, mitigating oxidative stress and cholesterol transport disturbances. Together, these drugs restore normal cell-cell communication, reduce hippocampal atrophy, and partly reverse hallmark AD pathology such as phosphorylated tau (p-tau) deposition and amyloid-beta (Aβ) plaque burden, which are key drivers of cognitive decline.
This discovery arose from computational analysis of medical records indicating that patients on these drugs had a lower likelihood of developing Alzheimer's. The preclinical experiments in mice validated the drugs' effects on brain pathology and cognition, suggesting a novel avenue for Alzheimer's treatment that could bypass the lengthy process of new drug development by repurposing existing therapies.
If these drugs are shown to work in humans, they could change how Alzheimer's is treated, offering a new therapeutic strategy for a condition that has long been difficult to address. Letrozole is a drug used to treat breast cancer, and Irinotecan is prescribed for colon and lung cancers. By targeting tau proteins, Letrozole and Irinotecan show promise in reversing some of the damage caused by Alzheimer's.
Further research and clinical trials will be essential to determine whether Letrozole and Irinotecan can live up to their potential. If successful, they could be repurposed for Alzheimer's treatment, providing a much-needed solution for the millions affected by the disease. This discovery marks an exciting step toward finding new ways to treat Alzheimer's and highlights the possibility of repurposing existing drugs for other complex diseases.
The research on Letrozole and Irinotecan for Alzheimer's treatment has been published in the journal Cell. If these drugs prove effective in humans, they could offer hope to the millions of people affected by Alzheimer's worldwide.
- This discovery could lead to new therapies and treatments for neurological disorders like Alzheimer's disease, as researchers at UCSF and the Gladstone Institutes found that a combination of Letrozole and Irinotecan, originally used for cancer, can reduce tau protein clumps in the brain and improve cognitive functions.
- Health-and-wellness professionals should keep an eye on the progress of ongoing research, as the FDA-approved drugs Letrozole and Irinotecan, which target tau proteins, may offer a much-needed solution for medical-conditions such as Alzheimer's disease and other neurological disorders.
- Should Letrozole and Irinotecan prove effective in human clinical trials, their repurposing for the treatment of Alzheimer's disease could revolutionize health-and-wellness practices by providing new therapies and treatments for this debilitating condition affecting over 55 million people worldwide.
